Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Other Working Capital Changes (2017 - 2025)

Arcus Biosciences has reported Other Working Capital Changes over the past 9 years, most recently at -$252.0 million for Q4 2025.

  • Quarterly results put Other Working Capital Changes at -$252.0 million for Q4 2025, down 334.48% from a year ago — trailing twelve months through Dec 2025 was -$240.0 million (down 328.57% YoY), and the annual figure for FY2025 was -$240.0 million, down 328.57%.
  • Other Working Capital Changes for Q4 2025 was -$252.0 million at Arcus Biosciences, down from $200.0 million in the prior quarter.
  • Over the last five years, Other Working Capital Changes for RCUS hit a ceiling of $200.0 million in Q3 2025 and a floor of -$252.0 million in Q4 2025.
  • Median Other Working Capital Changes over the past 5 years was -$21.0 million (2023), compared with a mean of -$15.5 million.
  • Biggest five-year swings in Other Working Capital Changes: tumbled 49900.0% in 2022 and later skyrocketed 359.38% in 2024.
  • Arcus Biosciences' Other Working Capital Changes stood at $45.4 million in 2021, then rose by 5.77% to $48.0 million in 2022, then changed by 0.0% to $48.0 million in 2023, then tumbled by 220.83% to -$58.0 million in 2024, then crashed by 334.48% to -$252.0 million in 2025.
  • The last three reported values for Other Working Capital Changes were -$252.0 million (Q4 2025), $200.0 million (Q3 2025), and -$171.0 million (Q2 2025) per Business Quant data.